Navigation Links
Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
Date:9/24/2007

- Publication in Leading Peer-Reviewed Journal Represents Further Scientific Validation of the Potential Utility of Modigene's CTP Technology

-

VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today reported that researchers will publish a study in the October edition of the journal Endocrinology showing that erythropoietin (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased the half-life of standard EPO in animal models.(1) The study, which assessed an early version of EPO-CTP, showed that a single weekly injection was as effective in raising hematocrit levels as the same total dose of standard EPO administered in three injections over the course of a week.

The current version of EPO-CTP in preclinical development at Modigene has further extended the duration of the drug, demonstrating in animal models an approximately 33% longer half-life and greater biological activity than Aranesp(R), Amgen's long-acting EPO.

"The publication of this study in the respected journal Endocrinology further validates the growing body of clinical and preclinical data supporting the ability of CTP technology to significantly extend the half-life and duration of action of therapeutic proteins," said Dr. Fuad Fares, lead author of the study and Chief Scientific Officer of Modigene. "Long-acting therapeutic protein drugs are increasingly important treatments for a variety of diseases, and we believe the demonstrated ability of our CTP technology to reduce the frequency of required injections could provide important benefits to the many patients who depend on these drugs. We look forward to advancing our first CTP-enhanced drug candidates into clinical trials next year."

Modigene is conducting late-stage preclinical studies of CTP-enhanced protein drugs including human growth hormone, interferon beta and EPO. All three have demonstrated s
'/>"/>

SOURCE Modigene Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)...  Results of the recent study, Results From ... Intra-Operative Positive Margin Detection , were presented as part ... Annual Miami Breast Cancer Conference last week. ... , MD, FACS, Professor of Surgery at the Sackler ... analysis of MarginProbe,s efficiency and accuracy when used consecutively ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
... Sept. 16 ScriptPro has been awarded a contract ... National Institutes of Health (NIH) in Bethesda, ... drug information systems will be implemented in the National ... and identification of drugs and enhance the safety and ...
... YORK, Sept. 16 Reportlinker.com announces that ... in its catalogue: Electrophysiology ... and Market Forecasts to 2016 ... Electrophysiology Devices - Global Pipeline Analysis, Opportunity ...
Cached Medicine Technology:National Institutes of Health Chooses ScriptPro for Pharmacy Automation 2Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... 04, 2015 The ability of ... density assessment and help improve breast cancer risk ... accepted for presentation at the European Congress of ... abstracts - eight posters and 2 session presentations ... breast density and quantitative breast imaging software tools ...
(Date:3/4/2015)... March 04, 2015 With the growing influence ... lives of our teens and young adults, combined with the ... and confusing to try to keep up with what kids ... or trend is replaced on a daily basis. , The ... and the slang that is used to discreetly talk about ...
(Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
... mental health bed in South Australia for every 100,000 people, ... of Australia is at 11. The amount of Government funding ... the lowest in the country. The number of mental health ... disease. ,The State spending towards mental health ...
... that nearly 1/3rd of our lifetime is spent for sleep. ... quantity. People who have odd working hours such as drivers, ... that is responsible for fatigue and other health disorders. ... have for the first time shed light on various aspects ...
... by the UK Department for Transport on the health disturbances ... the risk of developing deep vein thrombosis (DVT) could be ... the most comprehensive data published correlating DVT and travel. The ... form of travel, probably due to the immobility for a ...
... take place in the UK as many disfigured people are ... injuries is one among them. // Jacqueline Saburido has already ... see with her left eye. The first face transplant will ... ,About five patients will be identified by Butler, and ...
... of Ambylopia or lazy eye as it is commonly called. It ... the USC and three other Chinese universities. //,A lazy ... in the vision even when corrective glasses are used. If untreated, ... has been regarded to be incurable in children over 8 years. ...
... rapidly eliminate milder strains of avian influenza virus before it ... to broaden the target of the European Union regarding the ... by agricultural ministers of the 25 different countries that represent ... it was agreed to boost the currently existing surveillance of ...
Cached Medicine News:Health News:Reindeer Provide Valuable Insights Into Sleep Disorders 2Health News:Detection of Weak strains of bird flu virus – Target of European Unio 2
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Core Curriculum fills the gap between the preclinical pathophysiology texts and specialist volumes aimed at cardiologists. It covers clinical cardiology for medical students, cardiology tr...
... published by Unbound Medicine ... resource that combines evidence-based ... edge technology. It offers ... specifically engineered to provide ...
This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards....
Medicine Products: